117 / 244
PD-24
Characteristics of the nutritional status of the Korean diabetic
patients by the nutritional care process model
Eugene KIM
1,3
, Kyung Ae LEE
1,2
, Yu Ji KIM
1,2
, Tae Son PARK
1,2
*,
Heung Yong JIN
1,2
, Yong-Jin IM
4
, Youn-Soo CHA
3
,
Hong Sun BAEK
1,2
.
1
Research Institute of Clinical Medicine of
Chonbuk National University Hospital,
2
Medical School of Chonbuk
National University, Endocrinology & Metabolism,
3
Department of
Food Science and Human Nutrition, Chonbuk National,
4
Clinical Trial
Center and Biomedical Research Institute of Chonbuk National
University Hospital, Korea
Objectives:
This study was performed to examine nutrition
problems for according to the classification of nutritional care
process model developed by the International Dietetics and
Nutrition Terminology (IDNT).
Methods:
This study was conducted to 526 diabetic patients
received diet counseling visited Chonbuk National University
Hospital. The patients were divided four groups, normal
calorie group (NC, n = 100), over calorie group (OC, n = 135),
skip meal group (SM, n = 149), and under calorie group (UC,
n = 142) by their eating habits.
Results:
The calorie intake of SM (1,557.86 Kcal ± 657.89) was
significantly lower than the OC group (2,211.05 Kcal ± 601.24),
but was significantly higher than the UC group (1,202.2 Kcal
± 319.34) (p < 0.0001). The body weight of SM group (69.33 kg
± 16.2) was significantly higher than the OC group (64.39 kg ±
14.74) and UC group (63.75 kg ± 14.45)(p < 0.01). The results
suggest that the body weight is a significant impact eating
habits of regularly diet or skip meal diet more than total
calorie intake. In the laboratory results, albumin (p < 0.01),
lymphocyte count (p < 0.05), and hemoglobin level (p < 0.05) of
the UC group was significantly lower than the OC group. These
results suggest that albumin, lymphocyte count, and hemo-
globin were more significantly affected by the total calorie
intake than eating habits of diet.
Conclusions:
Our study showed that body weight of diabetic
patients was significantly affected by eating habits compare to
total caloric intake. Also, laboratory results such as albumin,
lymphocyte, and hemoglobin level were more affected by the
total calorie intake compare to body weight.
Our study recommended that diabetic patients individualized
nutrition care process is important and must be performed by
the dietician who had experienced in individualization
protocol, such as, IDNT.
PD-25
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor,
suppresses the progression of atherosclerosis in diabetic apoE-
deficient mice
Saiko MURAKAMI
1
, Takeshi MATSUMURA
1
*,
Takafumi SENOKUCHI
1
, Norio ISHII
1
, Kazuki FUKUDA
1
,
Sarie YAMADA
1
, Yutaro MORITA
1
, Shuhei NISHIDA
1
,
Miki SATO
1
, Hiroyuki MOTOSHIMA
1
, Tatsuya KONDO
1
,
Eiichi ARAKI
1
.
1
Department of Metabolic Medicine, Faculty of Life
Sciences, Kumamoto University, Japan
Background:
Cardiovascular disease is one of the leading
causes of disability and death in subjects with diabetes.
Recently, sodium-glucose cotransporter 2 inhibitors (SGLT-
2is) were developed as a novel class of drugs for type 2 diabetes
(T2D). A clinical study revealed that treatment with empagli-
flozin, one of the selective SGLT-2is, reduced the primary
composite cardiovascular events in patients with T2D.
However, it is not well known whether SGLT-2is itself can
prevent the progression of diabetic macroangiopathy. In this
study, we investigate whether empagliflozin suppresses
progression of atherosclerosis in streptozotocin-induced dia-
betic apolipoprotein-E-deficient (diabetic apoE KO) mice.
Methods:
ApoE KO mice were obtained from Jakson laboratory
(Bar Harbor, ME). These mice were maintained on a C57BL/6
background. From 9 weeks of age, the mice received
intraperitoneal injections of saline or streptozotocin (100 mg/
kg). After 2 weeks of injection, development of diabetes inmice
was determined by measuring blood glucose level (>200 mg/
dL). Then mice were treated orally with empagliflozin (5 mg/
kg/day) (n = 8) or vehicle alone (water) as a control (n = 8). After
8 weeks of treatment, the mice were sacrificed and athero-
sclerotic lesions of aortic sinus and en-face of whole aortawere
prepared for immunohistochemistry. The whole aorta or
6-μm-thick frozen sections of the aortic sinus were obtained
fromApoE
–
/
–
mice and were stained with Oil red O. Lesion size
was measured on digital microphotographs of the aortic sinus
by measuring the stained surface area using ImageJ software.
Plasma total cholesterol, triglyceride, and HDL cholesterol
concentrations were measured at Skylight Biotech Inc., (Akita,
Japan).
Results:
Although there were no significant differences on
dietary intake and body weight between control group and
emapgliflozin group, casual blood glucose level was lower in
emapgliflozin group. Meal tolerance test demonstrated that
glucose levels at all time points were lower in emapgliflozin
group than in control group. On lipid profile, there were no
differences on total cholesterol level and triglyceride level
between control group and emapgliflozin group. However,
HDL-cholesterol level was significantly higher in emapgliflo-
zin group than in control group. Oil-Red-O staining of aortic
sinus and whole aorta demonstrated that size of atheroscler-
otic lesions was decreased in emapgliflozin group than in
control group.
Conclusion:
This study provides the first evidence that
empagliflozin suppresses the progression of atherosclerosis
in diabetic apoE KO mice. These findings may indicate the
beneficial effects of SGLT-2is for the prevention of diabetic
macrovascular complications in subjects with T2D.
PD-26
Increased grip strengthwith SGLT2 inhibitors: Sub-analysis by
BMI, a new insight to EMPA-REG OUTCOME Study
Yoshihiko SUZUKI
1
*, Motoaki SANO
2
, Shu MEGURO
3
,
Toshihide KAWAI
4
, Junichiro IRIE
3
, Nobuhiro IKEMURA
2
.
1
HDC
Atlas Clinic,
2
Department of Cardiology, Keio University School of
Medicine,
3
Department of Internal Medicine, Keio University School of
Medicine,
4
Department of Internal Medicine, Saiseikai Central
Hospital, Tokyo, Japan
Maximal hand grip strength measurement could be a method
for cardiovascular risk stratification among patients with type
2 diabetes.
Materials and methods:
We examined the change in maximal
hand grip strength before and after sodium-glucose cotran-
sporter 2 inhibitor (SGLT2i) treatment. The study included 92
men and 20 women with type 2 diabetes in Japanese. The
patients were treated with ipragliflozin 50 mg, luseogliflozin
2.5 mg, or dapagliflozin 5 mg or 10 mg daily for at least 4 weeks.
The results showed that both the men and women had
increased grip strength in both hands (P < 0.01, paired T test).
In the sub-analysis, in men, grip strength (GS) of patients
whose BMI over 25 (n = 49) was 32.1 ± 1.1 kg (Mean ± SEM) in
right hand and 30.5 ± 1.0 kg in left hand at baseline. After
SGLT2i, GS of right hand increased to 34.3 ± 1.1 kg (p < 0.01),
and GS of left hand increased to 32.0 ± 1.1 kg (p < 0.01). GS of
patients whose BMI below 25 (n = 43) was 28.6 ± 1.1 kg in right
hand and 28.1 ± 1.2 kg in left hand at baseline. After SGLT2i, GS
of right hand increased to 29.5 + 1.2 kg(n.s.), but GS of left hand
was almost the same as 28.2 ± 1.1 kg (n.s.).
In women, GS of patients whose BMI over 25 (n = 11) was
18.5 ± 1.2 kg in right hand and 17.2 ± 1.0 kg in left hand at
baseline. After SGLT2i, GS of right hand increased to 20.6 ±
1.6 kg (n.s), and GS of left hand increased to 18.3 ± 1.2 kg (n.s.).
GS of patients whose BMI below 25 (n = 9) was 17.5 ± 1.2 kg in
right hand and 17.2 ± 0.9 kg in left hand at baseline. After
SGLT2i, GS of right hand increased to 20.0 ± 1.5 kg(n.s.), and GS
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65
–
S211
S99